Table 4 Univariate and multivariate analysis with distant metastasis for HR+/HER2− breast cancer not received chemotherapy
Parameters | Univarite analysis | Multivarite analysis | ||||
|---|---|---|---|---|---|---|
Odd ratio | 95% CI | p value | Odd ratio | 95% CI | p value | |
Age at operation (years old) | ||||||
 ≤ 60 versus > 60 | 0.455 | 0.101–2.048 | 0.299 |  |  |  |
Tumor size (mm) | ||||||
 ≤ 20.0 versus > 20.0 | 0.781 | 0.197–3.106 | 0.726 |  |  |  |
Tumor size (mm) | ||||||
 ≤ 30.0 versus > 30.0 | 0.343 | 0.037–3.161 | 0.328 |  |  |  |
Pathological lymph node metastasis | ||||||
pN0, pN1mi versus pN1a | 12.083 | 1.880–77.665 | 0.003 | 16.723 | 1.197–520.348 | 0.050 |
Progesterone receptor | ||||||
Negative versus positive | – | – | 0.284 |  |  |  |
Ki67 | ||||||
 ≤ 20% versus > 20% | 1.156 | 0.190–7.037 | 0.875 |  |  |  |
Surgical treatment | ||||||
BCT and radiation therapy versus mastectomy | 0.179 | 0.039–0.821 | 0.020 | 0.044 | 0.001–0.420 | 0.026 |
Lymphatic invasion | ||||||
ly0 versus ly1 | 1.280 | 0.322–5.088 | 0.726 |  |  |  |
Venous invasion | ||||||
v0 versus v1 | 1.450 | 0.118–17.766 | 0.770 |  |  |  |
Nuclear grade | ||||||
1, 2 versus 3 | 0.520 | 0.054–5.021 | 0.567 |  |  |  |
Adjuvant endocrine therapy | ||||||
TAM (+ LH-RH agonist) versus ANA | 0.867 | 0.217–3.461 | 0.839 |  |  |  |
Disease free survival (days) | ||||||
 ≤ 1462 versus > 1462 | 7.125 | 1.309–38.771 | 0.014 | 6.693 | 0.954–81.406 | 0.080 |
TILs density | ||||||
 ≤ 10 versus > 10 | 1.500 | 0.234–9.611 | 0.667 |  |  |  |
TILs | ||||||
Absent versus Not absent | 0.127 | 0.018–0.797 | 0.015 | 0.144 | 0.003–5.060 | 0.285 |